Silo Pharma Inc.

Last updated September 27, 2026

Organization details

Legal name
Silo Pharma Inc.
Former names
Uppercut Brands, Inc. Point Capital, Inc. Gold Swap Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Nevada
Headquarters city
Sarasota
Headquarters state / province
Florida
Headquarters country
United States
Fiscal year end
December
Ticker symbol
SILO
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001514183
EIN
46-2137136

Board of directors

Chief executives

Eric Weisblum · CEO and President
Dates unknown

Director election results

Annual meeting of August 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

2 of this board's directors also sit on 2 other boards. 1 is in the same sector.

Network of Silo Pharma Inc.'s board connections Rocket One Inc. Rocket One Inc. Myseum.AI Inc. Myseum.AI Inc. Jeff Pavell Jeff Pavell Wayne Linsley Wayne Linsley Silo Pharma Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$7,660
6 purchases by 1 insider
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Dec 15, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +2,500 $0.41 $1,025
Dec 15, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +2,500 $0.42 $1,050
Nov 21, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +1,000 $0.37 $370
Nov 20, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +1,000 $0.37 $370
Nov 19, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +4,500 $0.41 $1,845
Nov 18, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +7,500 $0.40 $3,000
May 27, 2025 Eric Weisblum Director, Officer (Chief Executive Officer) Open-market purchase +10,000 $0.43 $4,300
Dec 13, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +2,500 $0.84 $2,100
Nov 22, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +2,500 $0.90 $2,250
Nov 20, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +2,500 $0.95 $2,375
Jun 12, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +4,438 $1.11 $4,926
Jun 11, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +562 $1.08 $607
Apr 5, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +400 $2.03 $812
Apr 4, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +600 $1.96 $1,176
Apr 1, 2024 Eric Weisblum Director, Officer (CEO and President) Open-market purchase +1,100 $1.91 $2,101

Organizations in the same sector, closest in location and size first.

Questions about Silo Pharma Inc.

Who is the CEO of Silo Pharma Inc.?

Eric Weisblum is Silo Pharma Inc.'s CEO and President.

How many directors are on Silo Pharma Inc.'s board?

Silo Pharma Inc.'s board has 4 directors: Eric Weisblum, Jeff Pavell, Kevin Munoz and Wayne Linsley.

Are Silo Pharma Inc. insiders buying or selling shares?

Over the last 12 months, Silo Pharma Inc. insiders bought $7,660 of shares in 6 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="silo-pharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.